BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
It did have some patients that had received adjuvant therapy, but a small number. And they did not see a benefit to continuing checkpoints. So I think this is an unanswered question. All cancers behave differently, have a different biology. We know that bladder cancer is not kidney cancer. So I think we need to answer this question prospectively.
0
💬
0
Comments
Log in to comment.
There are no comments yet.